Daniel L. Menichella, BA, MBA
Chairman of the Executive Board / Chief Executive Officer
was appointed CEO of CureVac AG in June 2018. He joined CureVac in the beginning of 2017 as Chief Business Officer of CureVac AG and Chief Executive Officer of CureVac Inc. In this position, he was responsible for Business Development, Alliance Management and Commercial.
Dan has over 15 years of executive and leadership experience within the pharmaceutical and biotech fields, including CBO, SVP, and VP roles. Before joining CureVac, he was Chief Business Officer of Bamboo Therapeutics. Other stations in his career were Applied Genetic Technologies Corp., Zyngenia Inc., Talecris Biotherapeutics Holdings Corp. and Merck KGaA. Dan holds an MBA of the University of North Carolina and a BA from Harvard University.
Florian von der Mülbe, PhD, MBA
Chief Production Officer & Co-Founder
trained in biochemistry and business administration. Florian worked with Biotest GmbH and Roche AG before joining CureVac in 2000 - working with Ingmar Hoerr to build the business from the start. With CureVac he established the first GMP (good manufacturing practice) production for mRNA worldwide.
Previously, he worked with Prof. Jung at Tuebingen University. He holds a PhD in biochemistry from Tuebingen University and an MBA from the European School of Business in Reutlingen.
Mariola Fotin-Mleczek, PhD
Chief Technology Officer
trained in biology at the University of Stuttgart. Her scientific expertise includes immunology, cell biology, signal transduction, apoptosis and cellular uptake. She joined CureVac in Mai 2006 when she was responsible for the development and preclinical testing of RNActive® cancer vaccines. She is inventor of RNActive® related key patents and she authored several publications on mRNA technology.
Franz-Werner Haas, LLD, LLM
Chief Operating Officer
joined CureVac in June 2012. Before joining CureVac, he was Vice President Operations and Chief Compliance Officer of SYGNIS Pharma AG, where he was also responsible for the execution of M&A- and capital market transactions.
Franz-Werner Haas started his professional career as assistant to the Management of a privately held holding company before he assumed several management positions in the Life Science Industry, including Vice President and General Counsel of LION bioscience and General Counsel of Sirona Dental Systems. He studied law at the University of Saarbruecken, K.U. Leuven and the University of Edinburgh (LL.M.).
Ulrike Gnad-Vogt, MD
Chief Medical Officer
is a board certified medical oncologist and hematologist who worked as attending oncologist at the National Center for tumor diseases (NCT) in Heidelberg before joining CureVac in 2011.
Previously Ulrike was global medical leader for the early clinical and translational development of immunocytokines and a peptide cancer vaccine at Merck Serono in Darmstadt. Ulrike holds a medical degree from the University of Homburg/Saar and received training in internal medicine, hematology and oncology at the University of Mannheim.
Pierre Kemula, B.Sc.
Chief Financial Officer
joined CureVac in October 2016. Before joining CureVac, he was Chief Financial Officer of Pixium Vision where he successfully contributed to the listing of the company on Euronext in Paris, and Vice President Corporate Finance, Treasury and Financial Markets at Ipsen. He had earlier worked with major strategy consulting firms (Roland Berger, Bossard Consultants and Gemini Consulting). He holds a Bachelor of Science in Management Sciences from the London School of Economics (LSE) in the United Kingdom.